top of page

Speakers 2022

Dr. Aubrey de Grey is an English author and biomedical gerontologist. He is the author of The Mitochondrial Free Radical Theory of Aging and co-author of Ending Aging. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Ageing Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives talks at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Aubrey de Grey

Guenther is a Partner at PwC Zurich and Leader of PwC Legal Switzerland. He is also one of seven members of PwC’s Global Legal Leadership Team and PwC Legal’s Global LegalTech Leader. 

He is the author of 10 books mostly on investment law and regulation but also of “Making Money out of Technology”, “Uptake Revisited: How Innovative Products Succeed in International Markets” and “New Suits. Appetite for Disruption in the Legal World”. Guenther is also the host of the educational video series „Appetite for Disruption“, the founder of global technology enthusiasts movement Disruption Disciples, Co-Host of Legal Hackers Zurich, and a permanent member of expert groups at economiesuisse, the Swiss Fund and Asset Management Association and the Swiss Fintech Innovation Association.

Guenther Dobrauz

Partner and Leader, PwC Legal Switzerland

Stephanie Dainow is Executive Director at [Lifespan Extension Advocacy Foundation], a US based non-profit accelerating biomedical technologies that will increase healthy human lifespan through responsible journalism, research funding, advocacy, education and decentralizing aging research.  She is also a Business Mentor to SOSV’s IndieBio venture fund and accelerator, consulting deep tech startup founders on business development and strategy, fundraising and executive leadership. 

Previously, Stephanie was with Singularity University in Silicon Valley working across their Innovation Consultancy, Tech Think Tank, University for the Future, and Impact-based Startup Incubator.  She also worked for a global management consultancy as a Life Sciences Business Manager and served as Account Director for BioMarin Pharmaceutical.  Her early career in NYC spanned global growth for Interpublic Group’s media arm, celebrity and brand marketing, and commercial entertainment. 

Stephanie has volunteered around the world and previously held an Advisory Board position at a 501c3 that inspires Harlem youth to pursue STEM careers. She is passionate about empowering leaders to think differently about emerging technologies, disruption, and the future of corporate business.

Stephanie Dainow

Executive Director,

As Editor-in-Chief of Longevity.Technology Phil oversees daily news and market research to address the crossover between longevity science and investment. This news platform has fast become the #1 for daily news and insights.

As founder of First Longevity Phil and his team help to prepare longevity science and technology businesses for equity funding ahead of introducing deals to, and syndicating deals among, VCs, family offices, and HNWs.

Prior to focusing exclusively on longevity, Phil has applied his marketing and business development expertise at c-level into: IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability markets.

Phil Newman

Founder, First Longevity, Editor-in-Chief Longevity.Technology

Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging.

He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging.

Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.

Nir Barzilai

Director, Institute for Aging Research, Albert Einstein College of Medicine

Simone is CEO of Clinique La Prairie, one of the most iconic Swiss brands, where he is driving its international development and its diversification strategy, with the mission of creating a global player able to help people live a longer, healthier and better life.

Simone is CEO and co-founder of Clinique La Prairie Holistic Health, a leading ultraluxury company in “Longevity Supplements”.

Simone serves on the board of various companies in the field of Cosmetics, Health and Genetics. He writes and teaches (in business school and universities) about marketing, brand building, strategy, and organisational subjects.

Simone Gibertoni

CEO, Clinique La Prairie

After starting his first company at the age of 15, over the past 20 years Rob has accumulated a broad range of experience in the fields of entrepreneurship, strategic consulting and international management. 

After consulting some of the leading health and pharmaceutical companies during his time with one of the BIG4 professional services firms, he served as Head of International Marketing for the leading Swiss retail group with over 25 individual companies, co-founded a software company and was CEO of two renowned companies in the field of International Health Insurance and Health Management. 

As a longevity enthusiast and life-long tech geek, he believes the more you know about your body, the more you can improve your health and wellbeing, and is developing solutions and programs to help people do exactly that. Rob also holds a doctorate in Public Healthcare Management.

Rob Konrad Maciejewski

Co-Founder and CEO, Biolytica

Eric oversees BIOAGE’s clinical and computational efforts to bring new therapeutics to the clinic that target fundamental mechanisms of aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. He completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.

Eric Morgen

Co-Founder and COO, BioAge

Dr. sc. med. Elena Gross is the founder and CEO of KetoSwiss, a Swiss biotech startup, winner of this year's Top 100 Swiss startup public award. KetoSwiss develops highly potent therapeutic ketones for neurological disease prevention.

Elena started her career in academia. She used to be a chronic migraine patient and due to the lack of tolerable and efficacious treatment options, she pursued an MSc in Neuroscience at the University of Oxford. There, she discovered ketone bodies & their potential therapeutic use in neurological disease, which changed her life. 

Entrepreneurial in spirit, she is the inventor of two patents. She also initiated & funded the first ever clinical trial using exogenous ketone body salts in the world in her PhD at the University of Basel and University of Harvard Medical School.

Elena Gross

Founder and CEO, KetoSwiss

Amy Killen, MD is a leading regenerative physician with a focus on sexual optimization as a
driver for health and longevity. In her Utah-based practice she combines stem cell injections with photobiomodulation, shockwave therapy, body-identical hormones,
nutritional supplements, peptides and old-fashioned healthy lifestyle to give patients unparalleled synergistic regenerative effects for sexual systems.

Dr. Killen is also the founder and CEO of the Human Optimization Project, a
longevity-focused nutritional supplement and education platform that makes staying on
top of current trends in aging prevention easy and fun, and she is on the core team of Reputable, a decentralized science platform that incentivizes betterment experiments and aggregates N of 1 data into actionable insights.

She practiced emergency medicine for ten years before transitioning to longevity and
regenerative medicine. She now divides her time between clinical work, international
speaking engagements, educational content creation, her entrepreneurial endeavors and her family of five.

Amy Killen

Longevity and regenerative medicine physician, entrepreneur, educator

Dr. Emil Kendziorra is a founder and CEO at Tomorrow Biostasis GmbH based in Berlin, Germany, and President of the Board at European Biostasis Foundation, a non-profit research foundation in Switzerland.

He has a strong background in medicine, cancer research, and entrepreneurship. He has been CEO of multiple tech and medical companies, most recently as a Founder and CEO of Medlanes (Exit to ZAVA) and onFeedback (Exit to QuestionPro).

Emil graduated summa cum laude in medicine from the University Medical Center Göttingen - one of the leading medical schools in Germany - with a doctoral degree in translational cancer research. He’s a regular keynote speaker on future of healthcare policy, the overlap of healthcare, science, and technology as well as an advisor to insurances, hospital chains, and pharmaceutical companies on digitalization topics.

Furthermore, he’s a mentor to a wide range of startups and (rarely) an early-stage angel investor. 

Emil has decided to dedicate the next decades of his life to Medical Biostasis and cryomedicine.

Emil Kendziorra

CEO and Managing Partner, Tomorrow Biostasis

Olga's career journey started with a nutritionist degree and led her to pursue her passion for all research and sciences related to holistic health and wellness. She joined Clinique La Prairie in 2018, focusing on fostering the innovative approach of longevity, a field that is shaped by continuous overwhelming scientific findings. She describes her mission as a challenging yet inspiring task, as well as an important responsibility. Her specific areas of expertise include weight management, detoxification approach, metabolic health, revitalization treatments and nutraceuticals. Olga explores the potential of precision medicine, nutrition and individualized plans combined with cutting-edge longevity technologies, advanced treatments, and innovative clinical approach, to continuously enhance Clinique La Prairie’s programs in collaboration with the clinic’s experts.

Olga Donica

Head of Innovation and Research in Longevity, Clinique La Prairie

bottom of page